Sugi Predict

Sugi Predict / Compounds / SCHEMBL4746064

SCHEMBL4746064

SCHEMBL4746064

Fc1cc(F)cc(-c2cc(Cl)c3nonc3c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPAS1 Q99814 9/20 0.37
▸ MAPT P10636 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ ARNT P27540 5/20 0.34
▸ L3MBTL1 Q9Y468 3/20 0.33
▸ APAF1 O14727 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ THRB P10828 2/20 0.33
▸ RECQL P46063 2/20 0.33
▸ BLM P54132 2/20 0.33
▸ SAE1 Q9UBE0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744894 0.79 MAPT (0.37) MAPTALDH1A1TP53LMNANPC1
SCHEMBL4744881 0.76 KIF11 (0.41) CASP3
SCHEMBL8159627 0.72 EPAS1 (0.35) EPAS1ARNT
SCHEMBL4786410 0.72 CASP3 (0.43) EPAS1MAPTALDH1A1TP53NPC1
SCHEMBL4743550 0.72 AKR1C2 (0.43) TP53NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL15571232 0.69 MAPT (0.37) EPAS1MAPTALDH1A1TP53LMNA
SCHEMBL4744895 0.69 GRIN2B (0.39) MAPTALDH1A1TP53LMNANPC1
SCHEMBL4745394 0.69 ADORA2A (0.44) MAPTALDH1A1TP53NPC1HPGD
SCHEMBL4746865 0.67 MEN1 (0.46) EPAS1MAPTALDH1A1TP53LMNA
SCHEMBL4746821 0.66 ALDH1A1 (0.43) ALDH1A1TP53LMNANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 — — EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 — — WO disclosed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 — — WO disclosed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 — — EP disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP EPAS1 1966/4885MAPT 1681/4885ALDH1A1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.